CAL103
Chronic inflammatory diseases (via oxPL target)
Discovery/PreclinicalActive
Key Facts
Indication
Chronic inflammatory diseases (via oxPL target)
Phase
Discovery/Preclinical
Status
Active
Company
About Calluna Pharma
Calluna Pharma is a clinical-stage biotech targeting the root causes of inflammation and fibrosis through a novel platform centered on Damage Associated Molecular Pattern (DAMP) proteins. Its lead asset, an anti-S100A4 antibody (CAL101), is in Phase 2 for IPF, with a broader pipeline targeting oxidized phospholipids (oxPLs) for other chronic inflammatory conditions. The company leverages over 30 years of foundational research from its co-founders and has established a key strategic alliance with Eli Lilly, positioning it to address significant unmet medical needs in large and growing markets.
View full company profile